Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lihui Lu

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Bioorganic & Medicinal Chemistry Letters|November 16, 2010
Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse modelsEugen F Mesaros, Jason P Burke, Jonathan D Parrish, et al.
Hematology (Amsterdam, Netherlands)|August 18, 2023
BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3Li Ma, Jianwei Wang, Yang Yang, et al.
Journal of Medicinal Chemistry|August 24, 2011
2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activityGregory R Ott, Gregory J Wells, Tho V Thieu, et al.
Cell Death & Disease|August 12, 2023
LMO2 promotes the development of AML through interaction with transcription co-regulator LDB1Lihui Lu, Jianwei Wang, Fang Fang, et al.
Journal of Medicinal Chemistry|December 7, 2011
Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1-f][1,2,4]triazines: identification of orally bioavailable, efficacious ALK inhibitorsEugen F Mesaros, Tho V Thieu, Gregory J Wells, et al.
Journal of Medicinal Chemistry|August 17, 2016
Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)Gregory R Ott, Mangeng Cheng, Keith S Learn, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Bioorganic & Medicinal Chemistry Letters|November 16, 2010
Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse modelsEugen F Mesaros, Jason P Burke, Jonathan D Parrish, et al.
Hematology (Amsterdam, Netherlands)|August 18, 2023
BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3Li Ma, Jianwei Wang, Yang Yang, et al.
Journal of Medicinal Chemistry|August 24, 2011
2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activityGregory R Ott, Gregory J Wells, Tho V Thieu, et al.
Cell Death & Disease|August 12, 2023
LMO2 promotes the development of AML through interaction with transcription co-regulator LDB1Lihui Lu, Jianwei Wang, Fang Fang, et al.
Journal of Medicinal Chemistry|December 7, 2011
Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1-f][1,2,4]triazines: identification of orally bioavailable, efficacious ALK inhibitorsEugen F Mesaros, Tho V Thieu, Gregory J Wells, et al.
Journal of Medicinal Chemistry|August 17, 2016
Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)Gregory R Ott, Mangeng Cheng, Keith S Learn, et al.
Pageof 4